Autres langues Sysmex Corporation

Actions

6869

JP3351100007

Equipement, fournitures et distribution médicale

Marché Fermé - Japan Exchange 08:30:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
1 786,50 ^JPY	+0,42%		-8,29%	+15,82%

12/08	Transcript : Sysmex Corporation, Q1 2027 Earnings Call, Aug 07, 2026
10/08	Sysmex Corporation : Tokai Tokyo Securities relève sa recommandation à acheter	ZM

Autres langues

10/09	Sysmex Europe and Cytek(R) Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
07/08	Sysmex Q1 Profit Soars; Net Sales Climb
07/08	Sysmex Corporation Revises Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Full Year Ending March 31, 2027
24/07	Unternehmenskalender vom 27. bis 31. Juli 2026
22/07	Tranche Update on Sysmex Corporation's Equity Buyback Plan announced on March 5, 2026.
17/07	Sysmex : HIGH DIAGNOSTIC PERFORMANCE OF THE RANDOM-ACCESS HISCL pTAU-217, Aβ42 AND Aβ40 PLASMA ASSAYS IN DETECTING AMYLOID PATHOLOGY ACROSS CLINICAL STAGES
17/07	Sysmex : Plasma Endogenously Cleaved MTBR‑tau243 Measured By An Automated Immunoassay Is Associated With Tau PET-based Braak Staging
17/07	Sysmex : Longitudinal Changes in Blood-Based Biomarkers of Alzheimer’s Disease Across Age Groups and Their Associations with Cognitive Function
17/07	Validation Of Highly Specific And Automated Immunoassays For Endogenously Cleaved MTBR-tau243 In CSF: A Comparison With Mass Spectrometry
17/07	Sysmex Corporation's Equity Buyback announced on March 5, 2026, has closed with 21,138,200 shares, representing 3.41% for ¥29,999.88 million.
16/07	Sysmex : Presenting at the Alzheimer’s Association International Conference 2026 (AAIC 2026)
14/07	Assessment of aspirin response in neuroendovascular patients: comparison of five platelet function tests across light transmission aggregometry and a cartridge-based assay
14/07	Sysmex : Assessment of Platelet Function Between Low-Dose Prasugrel and Clopidogrel in Patients Undergoing Neuroendovascular Treatment
14/07	Sysmex : Method Comparison of the Revohem Anti-Xa LRT assay Compared to Other Commercial Reagents – Monitoring of Xa-Direct oral anticoagulants
02/07	Tranche Update on Sysmex Corporation's Equity Buyback Plan announced on March 5, 2026.
01/07	Sysmex : Genetic Testing Using Sysmex’s Assay Kit Receives Insurance Coverage as the First of Its Kind in Japan for Assessing the Risk of Adverse Reactions to Anti-Amyloid β Antibody Drugs
29/06	Sysmex : Selected as One of the World's Most Sustainable Companies 2026 by TIME
26/06	Sysmex : Notice of Resolutions at the 59th Ordinary General Meeting of Shareholders
22/06	Sysmex Corporation(TSE:6869) added to S&P Japan Mid Cap 100
22/06	Sysmex Corporation(TSE:6869) dropped from S&P Global 1200
22/06	Sysmex Corporation(TSE:6869) dropped from S&P International 700
22/06	Sysmex Corporation(TSE:6869) dropped from S&P TOPIX
17/06	VolitionRx Limited And Sysmex Corporation Announce Collaboration To Optimize Nu.Q NETs H3.1 Assay On Sysmex Platform
17/06	VolitionRx Collaborates With Japan's Sysmex for Optimization on Platform
14/05	Sysmex : Financial Statements( PDF format / 306KB )